<DOC>
	<DOCNO>NCT00129623</DOCNO>
	<brief_summary>This 2 arm study evaluate efficacy safety oral Bonviva 150mg monthly compare placebo post-menopausal woman osteopenia . Patients randomize receive either Bonviva 150mg po monthly , placebo monthly . The anticipated time study treatment 1-2 year , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Bonviva ( Ibandronate ) Once Monthly Post-Menopausal Women With Osteopenia</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>woman 4560 year age ; postmenopausal ; ambulatory . vertebral fracture ( except traumatic fracture motor vehicle accident ) ; lowtrauma osteoporotic fracture bone ; breast cancer diagnose within last 20 year ; malignancy diagnose within last 10 year , except successfully resect basal cell cancer ; treatment bisphosphonate within last 2 year ; treatment drug affect bone metabolism within last 6 month .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>